News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chiron Corporation (CHIR) Confirms Proposed Purchase Of BETASERON Assets By Schering AG (SHR) Under Change-In-Control Option



2/27/2006 10:35:20 AM

EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb. 24, 2006--Chiron Corporation (Nasdaq:CHIR) today announced that Schering AG has provided formal notice to Chiron of its intention to exercise its option under its collaboration agreement with Chiron to purchase or lease all assets used by Chiron in the manufacture for Schering of BETASERON(R) interferon beta-1b products and all contractual rights at their fair market or lease value. The purchase/lease option, as stipulated in a change-in-control clause in the agreement, is subject to the closing of the proposed acquisition of Chiron by Novartis AG. The agreement requires that the value be determined by an independent third party mutually agreed upon by both parties. The collaboration agreement between Chiron and Schering is set to expire in October 2008.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES